DK155143B - Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet - Google Patents
Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet Download PDFInfo
- Publication number
- DK155143B DK155143B DK420385A DK420385A DK155143B DK 155143 B DK155143 B DK 155143B DK 420385 A DK420385 A DK 420385A DK 420385 A DK420385 A DK 420385A DK 155143 B DK155143 B DK 155143B
- Authority
- DK
- Denmark
- Prior art keywords
- breast
- treatment
- pct
- administration
- antioestrogent
- Prior art date
Links
- 210000000481 breast Anatomy 0.000 title claims abstract description 8
- 230000001833 anti-estrogenic effect Effects 0.000 claims abstract description 10
- 239000000328 estrogen antagonist Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000011149 active material Substances 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract description 6
- 229940046836 anti-estrogen Drugs 0.000 abstract description 5
- -1 p-dimethylaminoethoxyphenyl Chemical group 0.000 abstract description 5
- 239000000186 progesterone Substances 0.000 abstract description 3
- 229960003387 progesterone Drugs 0.000 abstract description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 229960001603 tamoxifen Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000803 paradoxical effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- UHKJKVIZTFFFSB-UHFFFAOYSA-N 1,2-diphenylbutan-1-one Chemical compound C=1C=CC=CC=1C(CC)C(=O)C1=CC=CC=C1 UHKJKVIZTFFFSB-UHFFFAOYSA-N 0.000 description 1
- YOUWVLSTAZVPHM-UHFFFAOYSA-N 1-(4-hydroxyphenyl)-2-phenylbutan-1-one Chemical compound C=1C=CC=CC=1C(CC)C(=O)C1=CC=C(O)C=C1 YOUWVLSTAZVPHM-UHFFFAOYSA-N 0.000 description 1
- OBBFYFBJWYPOQQ-UHFFFAOYSA-N 1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbutan-1-one Chemical compound C=1C=CC=CC=1C(CC)C(=O)C1=CC=C(OCCN(C)C)C=C1 OBBFYFBJWYPOQQ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JNWNAQZSBRFGPC-UHFFFAOYSA-M magnesium;2-(phenoxy)oxane;bromide Chemical compound [Mg+2].[Br-].O1CCCCC1OC1=CC=[C-]C=C1 JNWNAQZSBRFGPC-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Description
DK 155143 B
i
Den foreliggende opfindelse angår et antiøstrogent lægemiddel af den i patentkravets indledning angivne art til behanlding af benigne og cancerøse tilstande i brystet, altså af visse former for svulster i brystkirtlen 5 i deres hormonafhængige former.
Der kendes allerede nu et antiøstrogen som kan indgives oralt, benævnt tamoxifen, som består af 1-[ρ-(β-dimetylaminoætoxy)-fenyl]-trans-l,2-difenylbut-l-en, der forhandles under specialitetsnavnet "Nolvadex". For 10 at opnå en antiøstrogenisk aktivitet på de østrogene receptorers niveau navnlig -i brystkirtlen, er det nødvendigt oralt at indgive fra 10 til 30 ml om dagen af denne forbindelse, og det bevirker skadelige bivirkninger, navnlig en paradoksisk stimulering af ovarierne.. Disse 15 sidstnævnte virkninger begrænser i høj grad udnyttelsen af tamoxifen.
Det er desuden påvist at tamoxifen efter oral indgift omdannes under passagen gennem leveren til talrige me-tabolitter, herunder 1—[p—(β-dimetylaminoætoxy)-fenyl]-20 trans-l-(p -hydroxyfenyl)-2-fenylbut-l-en eller 4-hydroxytamoxi- fen, der er den aktive form af produktet på molekylært niveau. På den anden side synes dette 4-hydroxyderivat indgivet direkte ad den orale vej at blive nedbrudt hurtigere end tamoxifen, og af denne grund er det unyttigt 25 at indgive det ad denne vej. Desuden er det også kendt at 4-hydroxyderivatet er fra tyve til hundrede gange mere aktivt end tamoxifen som antiøstrogen på de østrogene receptorers niveau. Imidlertid følger indgiften oralt eller parenteralt ad anden vej end den perkutane 30 til en diffusion af dette produkt gennem organismen, hvilket blandt andet bevirker en skadelig paradoksisk stimulering af ovarierne.
Man har iøvrigt beskrevet 4-hydroxytamoxifenderi-vatet som et antiøstrogent middel med henblik på at ind-35 give det oralt eller muligvis parenteralt, idet administrationen selv er begrænset til en injektion. Som nævnt ovenfor synes oral.indgift at være af begrænset 2
DK 155143 B
effektivitet på grund af ødelæggelsen af selve forbindelsen ved indgreb af leveren, mens en injektion, der fører til indførelse af forbindelsen i blodkredsløbet, kan fremkalde de forannævnte skadelige virkninger på ovarierne 5 i kraft af en systemisk effekt.
Skriftet Chemical Abstracts, bind 96, nr. 9, 1.
Marts 1982, side 29, abstrakt 62664k, Columbus, Ohio, (fJSA) & Eur. J. Cancer Clin.. Oncol. 1981, 17(9), 1063-1065, M. Sluyser et al., "Effect of monihydroxytamoxi-10 fen om mouse mammary tumors", beskriver egenskaberne af monohydroxytamoxifen uden af specificere cis- eller trans-formen, og i sammenhæng med en pellet under huden og følgelig ikke perkutant.
Nærværende opfinderes arbejde gennem 15 år over 15 metabolismen af steroide hormoner som indgives i alkoholisk opløsning ad den perkutane vej har gjort det muligt at påvise (Journal of Clinical Investigation(USA) 1970, 4£:31) at den perkutane indgiftsvej for steroider med kort halveringstid tillader direkte adgang til 20 målorganet, mens oral eller selv intravenøs indgift af det samme steroid begunstiger metabolisme deraf i leveren på bekostning af den effektive koncentration i receptorvævene. De således fremkaldte lever-bypasses påvistes for første gang for testosteron (Journal of 25 Clinical Endocrinology and Metabolism (USA) 1969, 29;437) og derefter senere for progesteron (Journal of Clinical Endocrinology (USA) 1969, 2^:1590 og 1974, ,38:142 og Fransk patent nr. 2515041). I tilfælde af progesteron var det muligt at påvise at indgiften af dette steroid 30 i alkoholisk opløsning eller i en 60%s vandig alkoholisk gel tillod lokal retention i 48 timer af forbindelsen som var passeret gennem den kutane barriere (10%). I modsætning hertil ødelægges ved oral indgift 90% af den indgivne dosis ved den første passage gennem leveren.
35 Nærværende opfindere forsøgte derfor i deres un dersøgelser at administrere 4-hydroxytamoxifenderivatet perkutant for at undgå alle systemiske virkninger, og 3
DK 155143 B
det viste sig overraskende at denne forbindelse i 60%s alkoholisk opløsning, påført på hud der lå over cancerøse brystsvulster,viste sig at have evne til at passere gennem den kutane barriere og blive optaget på receptor-5 molekylerne i disse svulster. Nærværende ansøgere har i modsætning hertil iagttaget at tamoxifen ikke kan aktiveres til sit 4-hydroxyderivat ad den perkutane vej eftersom brystet ikke til sin disposition ligesom leveren har de enzymer der behøves til omdannelsen.
10 Det anti-østrogene lægemiddel afledt af tamoxifen, hvis· aktive bestanddel består af 1-[p-(3-dimetylaminoætoxy)-feny1]-trans-1-(p-hydroxy-fenyl)-2-fenylbut-l-en, benævnt 4-hydroxytamoxifen, foreligger ifølge opfindelsen som en vandig alkoholisk gel der 15 kan administreres perkutant, og om ønsket indeholder det kendte excipienter.
4-Hydroxytamoxifens overskriden af den kutane barriere blev påvist ved hjælp af spordoser af tritieret 4-hydroxytamoxifen påført i alkoholisk opløsning i 24 timer 20 før fjernelse af cancerøse bryster. Undersøgelser udført i laboratorium viste at 4-hydroxytamoxifen viste sig i sin oprindelige form på niveauet for de proteinstrukturer som svarer til hormonale receptorer. Det har derfor evne til at have antiøstrogen virkning på dette niveau.
25 En lille portion af radioaktiviteten metaboliseres til uidentificerede produkter (3%). I parallelforsøg på-førtes dette samme produkt i radioaktiv form på huden af et rask individ og der fortoges beregning af den radioaktivitet som viste sig i urinen i løbet af 15 dage ' 30 efter indgiften af produktet. Hastigheden af elimina tionen med urinen viser at der sker en svag og gradvis nedbrydning af produktet. I det cirkulerende blod kan der kun opdages spor af produktet - der finder følgelig ingen akkumulering sted. Det er kun som sekundær effekt 35 at stoffet når leveren, hvor det inaktiveres.
Den kendsgerning at 4-hydroxytamoxifen er opløseligt i alkohol og kan absorberes af huden 4
DK 155143 B
gør det muligt at oparbejde denne forbindelse som en alkoholisk gel der egner sig til perkutan administration, og nærværende ansøgeres undersøgelser har vist en koefficient for kutan absorption nær ved 1% for 4-hydroxytamoxi-5 fen. På i og for sig kendt måde indeholder den alkoholiske gel foruden 4-hydroxytamoxifen forskellige excipienter der behøves til konditionering og for at gøre det muligt, at perkutan penetration finder sted, navnlig "Carbopol"^ ætylalkohol og vand. De daglige doser af produktet til ad-10 ministration kan let beregnes ved hjælp af absorptionskoefficienter af lægemidlerne og de doser som det ønskes at opnå for 4-hydroxytamoxifen på niveauet for dets receptormolekyler .
Et præparat af en gel ifølge opfindelsen til perku-15 tan administration angives nedenfor som eksempel der ikke på nogen måde er begrænsende: 4-hydroxytamoxifen 0,15 g 20 "Carbopol"® 934 1 g
Triætanolamin 1,5 g 95%s ætylalkohol 50 ml
Vand, indtil 100 g © 25 ("Carbopol" 934 er en karboxyvmylpolymer med ak tive karboxylgrupper, der bidrager til at danne stabile emulsioner med aminer).
30 Ved perkutan administration på brystet koncentrerer disse produkter sig selektivt i brystkirtlen og elimineres derefter med forsvindende hastigheder i biologiske væsker. Den opnåede effekt er den modsatte af den der iagttages i tilfælde af oral indgift, hvor der må opnås 35 en høj plasmakoncentration for at få en lav lokal koncentration. I tilfælde af perkutan indgift er hastig- 5
DK 155143 B
hederne maksimale nær ved indgiftsstedet og minimale i blodkredsløbet og leveren. Denne teknik tilfredsstiller derfor den opstillede fordring: topisk antiøstro-gen medicinbehandling med mulig sigte på behandling (syg-5 dom i brystet) og uden skadelige bivirkninger.
Teknikken med topisk 4-hydroxytamoxifen-administra-tion er derfor tilpasset på en sådan måde at der frembringes optimering af virkningerne af et antiøstrogen på et specifikt målorgan. Ingen anden medicinbehandling til-10 fredsstiller disse standarder.
Fremstilling af 4-hydroxytamoxifen er i og for sig kendt og kan fx udføres i henhold til en modifikation af den syntese som er beskrevet af Robertson og Katzenel-lenbogen (J. Org. Chem. 1982, 47, 2387, og J. Steroid, 15 Biochem. 1982, 16, 1), der finder sted i flere trin: 1) Reaktion mellem 4-(β-dimetylaminoætoxy)-a-ætyl-deoxybenzoin og p-(2-tetrahydropyranyloxy)-fenylmagne-siumbromid; 20 2) særskilt herfra dannelse af l-(4-hydroxyfenyl)-2- fenyl-l-butanon ved hydroxylering af 1,2-difenyl-l-bu-tanon; 3) omsætning mellem produkterne (1) og (2) fører til dannelse af l-[p-(6-dimetylaminoætoxy)-fenyl]-l-[p-(2- 25 tetrahydropyranyloxy)-fenyl]-2-fenylbutan-l-ol; 4) dehydratisering med metanol/saltsyre frembringer.
1-[p-(β-dimetylaminoætoxy)-fenyl]-trans-1-(p-hydroxy-fenyl)-2-fenylbut-l-en = 4-OH-tamoxifan, en blanding af cis- og trans-isomerer; 30 5) adskillelse af cis- og trans-isomeren ved kroma- tografering og krystallisation til konstant specifik aktivitet.
35
Claims (1)
- DK 155143 B Antiøstrogent lægemiddel til behandling af benigne og cancerøse tilstande i brystet og i hvilket det virk-5 somme materiale består af 1-[p-(/3-dimetylaminoætoxy)-fenyl]-trans-1-(p-hydroxyfenylj-2-fenylbut-1-en, kendetegnet ved at det foreligger som en gel af vandig alkoholisk type, der kan administreres ad den perkutane vej, og om ønsket indeholder i og for sig kendte excipienter. 10 15 20 25 • - f 30 35
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8400927A FR2558373B1 (fr) | 1984-01-20 | 1984-01-20 | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
| FR8400927 | 1984-01-20 | ||
| PCT/EP1984/000436 WO1985003228A1 (fr) | 1984-01-20 | 1984-12-21 | Medicament antioestrogene pour administration percutanee |
| EP8400436 | 1984-12-21 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| DK420385D0 DK420385D0 (da) | 1985-09-17 |
| DK420385A DK420385A (da) | 1985-09-17 |
| DK155143B true DK155143B (da) | 1989-02-20 |
| DK155143C DK155143C (da) | 1989-07-03 |
Family
ID=9300348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK420385A DK155143C (da) | 1984-01-20 | 1985-09-17 | Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4919937A (da) |
| EP (2) | EP0151326B1 (da) |
| JP (1) | JPH0667826B2 (da) |
| AT (1) | ATE73334T1 (da) |
| DE (1) | DE3485581D1 (da) |
| DK (1) | DK155143C (da) |
| FR (1) | FR2558373B1 (da) |
| WO (1) | WO1985003228A1 (da) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8604528D0 (en) * | 1986-02-24 | 1986-04-03 | Ici Plc | Therapeutic agents |
| PH30747A (en) * | 1989-03-10 | 1997-10-17 | Endorech Inc | Combination therapy for the treatment of estrogen sensitive disease. |
| US5119827A (en) * | 1990-09-05 | 1992-06-09 | Board Of Regents, The University Of Texas System | Mechanisms of antiestrogen resistance in breast cancer |
| US5518734A (en) * | 1991-09-25 | 1996-05-21 | Beta Pharmaceuticals Co. | Transdermal delivery system for estradiol and process for manufacturing said device |
| US5705185A (en) * | 1991-09-25 | 1998-01-06 | Beta Pharmaceuticals Co. | Transdermal delivery of estradiol and process for manufacturing said device |
| GB9207437D0 (en) * | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| DE4407742C1 (de) * | 1994-03-08 | 1995-06-22 | Hexal Pharma Gmbh | Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat |
| ES2156361T5 (es) * | 1996-03-29 | 2012-12-26 | Keyvest Gmbh | Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis" |
| RU2123838C1 (ru) * | 1996-07-31 | 1998-12-27 | Акционерное общество открытого типа "Нижфарм" | Состав для лечения гирсутизма |
| EP0943333A1 (de) * | 1998-03-18 | 1999-09-22 | S.W. Patentverwertungs GmbH | Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen |
| US20020086856A1 (en) | 1998-03-18 | 2002-07-04 | Alfred Schmidt | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| FI982733L (fi) | 1998-12-17 | 2000-06-18 | Orion Yhtymae Oyj | Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia |
| US7863011B2 (en) * | 2000-05-10 | 2011-01-04 | Signe Biopharma, Inc. | Screening method for predicting susceptibility to breast cancer |
| US8119138B2 (en) * | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
| US7947463B2 (en) | 2000-05-10 | 2011-05-24 | Signe Biopharma, Inc. | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| DE10054294A1 (de) * | 2000-11-02 | 2002-05-16 | Heinrich Wieland | Topische Behandlung bei der Mastalgie |
| AU2002359401A1 (en) * | 2001-11-14 | 2003-05-26 | David A. Sirbasku | Anti-estrogen and immune modulator combinations for treating breast cancer |
| AU2002366800B2 (en) | 2001-12-20 | 2006-08-03 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
| EP2050443B1 (en) * | 2002-12-18 | 2017-05-24 | Besins Healthcare Luxembourg SARL | Reduction of breast density with 4-hydroxy tamoxifen |
| EP1572178B1 (en) * | 2002-12-18 | 2006-05-03 | Laboratoires Besins International | Treatment of mastalgia with 4-hydroxy tamoxifen |
| US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| US7812010B2 (en) | 2003-01-02 | 2010-10-12 | Femmepharma, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| CA2519980C (en) * | 2003-04-01 | 2012-04-10 | Laboratoires Besins International | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| DE602004013439T2 (de) * | 2003-06-09 | 2009-06-04 | Ascend Therapeutics, Inc. | Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen |
| EP1550440A1 (en) * | 2003-12-15 | 2005-07-06 | Laboratoires Besins International | Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia |
| US7968532B2 (en) * | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| CA2549824C (en) * | 2003-12-15 | 2012-03-13 | Laboratoires Besins International | Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia |
| US7507769B2 (en) * | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| US20050208139A1 (en) * | 2004-03-22 | 2005-09-22 | Ascend Therapeutics, Inc. | Chemically stable compositions of 4-hydroxy tamoxifen |
| AU2005227072B2 (en) * | 2004-03-22 | 2010-08-19 | Besins Healthcare Luxembourg Sarl | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| EP1579856A1 (en) * | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| CA2582174C (en) * | 2004-10-14 | 2013-01-29 | Laboratoires Besins International | 4-hydroxy tamoxifen gel formulations |
| EP1647271A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
| US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
| RS52671B (sr) | 2005-10-12 | 2013-06-28 | Unimed Pharmaceuticals Llc | Poboljšani gel testosterona i postupak korišćenja |
| KR100850910B1 (ko) * | 2006-12-22 | 2008-08-07 | 삼성전자주식회사 | 블루투스 디바이스를 연결하기 위한 장치 및 방법 |
| EP2104489A2 (en) * | 2006-12-26 | 2009-09-30 | FemmePharma Holding Company, Inc. | Topical administration of danazol |
| US20110003000A1 (en) * | 2009-07-06 | 2011-01-06 | Femmepharma Holding Company, Inc. | Transvaginal Delivery of Drugs |
| EP3484463B1 (en) | 2016-08-19 | 2020-02-12 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0002097B1 (en) * | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
| DE3046719C2 (de) * | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| FR2515041A1 (fr) | 1981-10-26 | 1983-04-29 | Besins Jean | Medicament a base de progesterone pour le traitement des affections mammaires |
-
1984
- 1984-01-20 FR FR8400927A patent/FR2558373B1/fr not_active Expired
- 1984-12-19 EP EP84201920A patent/EP0151326B1/fr not_active Expired
- 1984-12-21 AT AT85900469T patent/ATE73334T1/de not_active IP Right Cessation
- 1984-12-21 WO PCT/EP1984/000436 patent/WO1985003228A1/fr not_active Ceased
- 1984-12-21 US US06/777,786 patent/US4919937A/en not_active Expired - Lifetime
- 1984-12-21 EP EP85900469A patent/EP0169214B1/fr not_active Expired - Lifetime
- 1984-12-21 DE DE8585900469T patent/DE3485581D1/de not_active Expired - Lifetime
- 1984-12-21 JP JP60500495A patent/JPH0667826B2/ja not_active Expired - Fee Related
-
1985
- 1985-09-17 DK DK420385A patent/DK155143C/da active
Also Published As
| Publication number | Publication date |
|---|---|
| DE3485581D1 (de) | 1992-04-16 |
| FR2558373B1 (fr) | 1987-07-03 |
| ATE73334T1 (de) | 1992-03-15 |
| DK420385D0 (da) | 1985-09-17 |
| DK420385A (da) | 1985-09-17 |
| EP0169214A1 (fr) | 1986-01-29 |
| JPH0667826B2 (ja) | 1994-08-31 |
| EP0169214B1 (fr) | 1992-03-11 |
| US4919937A (en) | 1990-04-24 |
| DK155143C (da) | 1989-07-03 |
| EP0151326B1 (fr) | 1989-07-12 |
| WO1985003228A1 (fr) | 1985-08-01 |
| FR2558373A1 (fr) | 1985-07-26 |
| EP0151326A1 (fr) | 1985-08-14 |
| JPS61500914A (ja) | 1986-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4919937A (en) | Percutaneous administration of tamoxifen | |
| Satyaswaroop et al. | Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice | |
| US4496556A (en) | Topical applications for preventing dry skin | |
| Ratko et al. | Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone | |
| Kammerau et al. | Absolute concentrations of dithranol and triacetyl-dithranol in the skin layers after local treatment: in vivo investigations with four different types of pharmaceutical vehicles | |
| JP2011052020A (ja) | ４−ヒドロキシタモキシフェンによる乳房密度低下 | |
| FARNSWORTH et al. | TESTOSTERONE METABOLISM IN THE PROSTATE 1, 2 | |
| CA2089373A1 (en) | Triarylethylene carboxylic acids with estrogenic activity | |
| JPS62126124A (ja) | 経皮投与用抗炎症鎮痛剤組成物 | |
| Zaino et al. | Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model | |
| Schoen et al. | Bilateral testicular tumors complicating congenital adrenocortical hyperplasia | |
| Berdusco et al. | Corticosteroid-binding globulin (CBG) production by hepatic and extra-hepatic sites in the ovine fetus; effects of CBG on glucocorticoid negative feedback on pituitary cells in vitro | |
| Chart et al. | Metabolism of salt-retaining hormone by surviving liver slices | |
| Gjessing | Studies of functional neural tumors: VI. Biochemical diagnosis | |
| Momo et al. | Assessment of indomethacin oral spray for the treatment of oropharyngeal mucositis-induced pain during anticancer therapy | |
| Penneys | Treatment of lichen sclerosus with potassium para-aminobenzoate | |
| PL186783B1 (pl) | Nowe [(3-propoksyfenoksy)etylo]dialkiloaminy, środek farmaceutyczny, zastosowanie nowych [(3-propoksyfenoksy)etylo]dialkiloamin i sposób ich wytwarzania | |
| CN1301165A (zh) | 预防和/或治疗乳腺癌的含类固醇芳香酶抑制剂的药物 | |
| Venturoli et al. | Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism | |
| JPS63145217A (ja) | 経皮投与組成物 | |
| DU VIVIER et al. | An animal model for evaluating the local and systemic effects of topically applied corticosteroids on epidermal DNA synthesis | |
| Pornel et al. | Efficacy and tolerability of Menorest® 50 compared with Estraderm® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study | |
| Ranney et al. | An azasterol that induces hypocholesterolemia in rats | |
| ZA200300085B (en) | 7-hydroxyepiandrosterone having neuroprotective activity. | |
| Ip et al. | Dichotomous effects of tamoxifen on a transplantable rat mammary tumor |